Type
. WHO disability grading: operational definitions. Leprosy review [Internet]. 2003;74(4):366-73. Available from: https://leprosyreview.org/article/74/4/36-6373
Type
. Unexplained delayed nerve impairment in leprosy after treatment. Leprosy review [Internet]. 2003;74(4):357-65. Available from: https://leprosyreview.org/article/74/4/35-7365
Type
. Treatment duration of reversal reaction: a reappraisal. Back to the past. Leprosy review [Internet]. 2003;74(4):328-36. Available from: https://leprosyreview.org/article/74/4/32-8336
Type
. Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials. Leprosy review [Internet]. 2003;74(4):319-27. Available from: https://leprosyreview.org/article/74/4/31-9327
Type
. Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3). Leprosy review [Internet]. 2003;74(4):311-8. Available from: https://leprosyreview.org/article/74/4/31-1318
Type
. The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Leprosy review [Internet]. 2003;74(4):300-10. Available from: https://leprosyreview.org/article/74/4/30-0310
Type
. Tangier disease--a diagnostic challenge in countries endemic for leprosy. Journal of neurology, neurosurgery, and psychiatry. 2004;75(2):301-4.
Type
. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature. 2004;427(6975):636-40.
Type
. Eureka moments. The Pharos of Alpha Omega Alpha-Honor Medical Society. Alpha Omega Alpha. 2003;66(4):43.
Type
. Eureka moments. The Pharos of Alpha Omega Alpha-Honor Medical Society. Alpha Omega Alpha. 2003;66(4):43.
Pagination
- Previous page
- Page 1884
- Next page